Investors & Media


  • Item Type:
  • Year:
  • 10 Mar. 2012

    Kamada Receives FDA Approval for Submission of IND for Clinical Trial of AAT by Inhalation

    Kamada Ltd. (TASE: KMDA) has obtained Food and Drug Administration (FDA) approval to conduct a clinical trial in the US for the company's next generation drug – an inhalable version of AAT (Alpha-1 Antitrypsin deficiency) for the treatment of cystic fibrosis.

  • 8 Mar. 2011

    Kamada Receives an Israeli Patent for its Ultrapure Transferrin for Pharmaceutical Compositions

    This is the second patent issued to Kamada under the same title after being granted with the same patent title by the United States Patent Office (USPTO).

  • 27 Oct. 2010

    Baxter announces launch of GLASSIA in the U.S.

    Baxter International Inc. (NYSE: BAX) today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.